These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35347553)

  • 1. Health state utilities for beta-thalassemia: a time trade-off study.
    Martin AP; Ferri Grazzi E; Mighiu C; Chevli M; Shah F; Maher L; Shaikh A; Sagar A; Hubberstey H; Franks B; Ramos-Goñi JM; Oppe M; Tang D
    Eur J Health Econ; 2023 Feb; 24(1):27-38. PubMed ID: 35347553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health state utilities associated with treatment for transfusion-dependent β-thalassemia.
    Matza LS; Paramore LC; Stewart KD; Karn H; Jobanputra M; Dietz AC
    Eur J Health Econ; 2020 Apr; 21(3):397-407. PubMed ID: 31828456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study.
    Joshi N; Hensen M; Patel S; Xu W; Lasch K; Stolk E
    Pharmacoeconomics; 2019 Jan; 37(1):85-92. PubMed ID: 30136178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of blood transfusions in β-thalassemia.
    Shah FT; Sayani F; Trompeter S; Drasar E; Piga A
    Blood Rev; 2019 Sep; 37():100588. PubMed ID: 31324412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.
    Scalone L; Mantovani LG; Krol M; Rofail D; Ravera S; Bisconte MG; Borgna-Pignatti C; Borsellino Z; Cianciulli P; Gallisai D; Prossomariti L; Stefàno I; Cappellini MD
    Curr Med Res Opin; 2008 Jul; 24(7):1905-17. PubMed ID: 18507891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
    Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
    Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
    Sruamsiri R; Chaiyakunapruk N; Pakakasama S; Sirireung S; Sripaiboonkij N; Bunworasate U; Hongeng S
    BMC Health Serv Res; 2013 Feb; 13():45. PubMed ID: 23379888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature.
    Lee TA; von Riedemann S; Tricta F
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):651-60. PubMed ID: 24918168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalassemia intermedia today: should patients regularly receive transfusions?
    Aessopos A; Kati M; Meletis J
    Transfusion; 2007 May; 47(5):792-800. PubMed ID: 17465943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalassemia: Common Clinical Queries in Management.
    Lal A; Bansal D
    Indian J Pediatr; 2020 Jan; 87(1):75-81. PubMed ID: 31620986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.
    Goulas V; Kouraklis-Symeonidis A; Manousou K; Lazaris V; Pairas G; Katsaouni P; Verigou E; Labropoulou V; Pesli V; Kaiafas P; Papageorgiou U; Symeonidis A
    Qual Life Res; 2021 Feb; 30(2):467-477. PubMed ID: 32920766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
    Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
    Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-thalassemia.
    Galanello R; Origa R
    Orphanet J Rare Dis; 2010 May; 5():11. PubMed ID: 20492708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.
    Ravangard R; Mirzaei Z; Keshavarz K; Haghpanah S; Karimi M
    Hematology; 2018 Aug; 23(7):417-422. PubMed ID: 29157136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
    Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalassemia Minor and Major: Current Management.
    Choudhry VP
    Indian J Pediatr; 2017 Aug; 84(8):607-611. PubMed ID: 28435994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
    Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
    Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.